ACRS (Aclaris Therapeutics) ROCE %: -58.56% (As of Mar. 2026)

What is Aclaris Therapeutics ROCE %?

Aclaris Therapeutics ACRS +2.50% 38 ROCE % is -58.56% as of Mar. 2026. GuruFocus rates ACRS with a GF Score™ of 38/100 and a GF Value™ of $0.45 (Significantly Overvalued). The stock has 9 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Aclaris Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -58.56%.

Aclaris Therapeutics (NAS:ACRS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Aclaris Therapeutics ROCE % Related Terms

Aclaris Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Aclaris Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aclaris Therapeutics ROCE % Chart

Aclaris Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-46.01

-36.95

-58.29

-29.58

-46.22

Aclaris Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-38.95	-39.91	-43.69	-63.42	-58.56

38GF Score

Aclaris Therapeutics Inc ACRS

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Aclaris Therapeutics ROCE % Calculation

Aclaris Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-74.075	/	( ( (220.327 - 31.596)	+	(160.46 - 28.645) )	/ 2 )
	=	-74.075	/	( (188.731	+	131.815)	/ 2 )
	=	-74.075	/	160.273
	=	-46.22 %

Aclaris Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-88.768	/	( ( (160.46 - 28.645)	+	(198.72 - 27.37) )	/ 2 )
	=	-88.768	/	( ( 131.815	+	171.35 )	/ 2 )
	=	-88.768	/	151.5825
	=	-58.56 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -58.56% mean?

Aclaris Therapeutics (ACRS) has a ROCE % of -58.56% as of Mar. 2026.

Is Aclaris Therapeutics' ROCE % too high?

Aclaris Therapeutics' current ROCE % is -58.56%. Overall, Aclaris Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Aclaris Therapeutics' ROCE % compare to IMMX and PRME?

Aclaris Therapeutics' ROCE % of -58.56% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Biotechnology company?

A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. Aclaris Therapeutics's current ROCE % is -58.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Aclaris Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Aclaris Therapeutics (ACRS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.45, compared to a current price of $4.92 — trading 993.3% above its estimated fair value. The current ROCE % is -58.56%. Aclaris Therapeutics' overall GF Score™ is 38/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Aclaris Therapeutics (ACRS), the current ROCE % is -58.56% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aclaris Therapeutics (ACRS) Overvalued in 2026?

Based on GuruFocus' analysis, Aclaris Therapeutics stock appears to be overvalued. The current stock price of $4.92 is trading 993.3% above its estimated GF Value™ of $0.45. GuruFocus considers Aclaris Therapeutics to be Significantly Overvalued.

Key valuation signals for ACRS:

ROCE %: -58.56%
GF Value™: $0.45 vs. price of $4.92 (993.3% above fair value)
GF Score™: 38/100 with 9 warning signs

No single metric tells the full story. See the ACRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aclaris Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies IMMX PRME CLYM SGP CABA DSGN DNA CRMD CADL ALT VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges 0H8T:UK 8AT:Germany

Address 701 Lee Road, Suite 103, Wayne, PA, USA, 19087

Website https://www.aclaristx.com

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

38GF Score

Get the complete analysis for ACRS

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.92

Price

$0.45

GF Value

View ACRS Analysis

See ROCE % data for all stocks →